SAKK 36/13–IBRUTINIB AND BORTEZOMIB FOLLOWED BY IBRUTINIB MAINTENANCE IN PATIENTS WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: PHASE I REPORT OF A PHASE I/II TRIAL. (June 2017) - Novak, U.